| Literature DB >> 33170853 |
Rebecca S B Fischer1,2, Jason M Unrine3, Chandan Vangala4, Wayne T Sanderson5, Sreedhar Mandayam6, Kristy O Murray1,7.
Abstract
BACKGROUND: Although there are several hypothesized etiologies of Mesoamerican Nephropathy (MeN), evidence has not yet pointed to the underlying cause. Exposure to various trace elements can cause the clinical features observed in MeN. METHODS ANDEntities:
Year: 2020 PMID: 33170853 PMCID: PMC7654766 DOI: 10.1371/journal.pone.0240988
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Definitions.
| Normal/Healthy | Normal serum creatinine (≤1.3 mg/dL for males or ≤1.1 mg/dL for females) |
| Incident AKI | Presentation with serum creatinine |
| • Baseline referenced to most recent normal measurement within 1 year prior to AKI event | |
| Renal Recovery | Return to normal serum creatinine (>1.3 mg/dL for males or >1.1 mg/dL for females) |
| • Maintained for ≥1 year following AKI event | |
| Incident CKD | Diagnosis by local nephrologist following ≥3 months of |
| • reduced glomerular filtration rate (<60mL/min/1.73m2), calculated from serum creatinine, or | |
| • functional or structural renal alteration, ascertained by blood, urine, or imaging studies | |
| MeN Diagnosis | Diagnosis by local nephrologist with renal disease (acute or chronic) that cannot reasonably be attributed to any known cause or underlying comorbidity, such as hypertension, diabetes, old age, obesity, or congenital deformity |
Characteristics of renal case patients and controls (N = 54).
| ALL | Case | Control | p-value | ||||
|---|---|---|---|---|---|---|---|
| N | N (%) | 18 (33.3%) | 36 (66.7%) | ||||
| Sex | |||||||
| Male | 54 | 49 (90.7%) | 14 (77.8%) | 35 (97.2%) | 0.038 | ||
| Female | 5 (9.3%) | 4 (22.2%) | 1 (2.8%) | ||||
| Age (years) | |||||||
| <25 | 54 | 17 (31.5%) | 7 (38.9%) | 10 (27.8%) | 0.733 | ||
| 25–29 | 13 (24.1%) | 5 (27.8%) | 8 (22.2%) | ||||
| 30–34 | 15 (27.8%) | 4 (22.2%) | 11 (30.6%) | ||||
| ≥35 | 9 (16.7%) | 2 (11.1%) | 7 (19.4%) | ||||
| Number of Years Working at Current Employer | |||||||
| = <2 | 51 | 10 (19.6%) | 5 (33.3%) | 5 (13.9%) | 0.184 | ||
| 3 to 6 | 18 (35.3%) | 6 (40%) | 12 (33.3%) | ||||
| 7 to 10 | 11 (21.6%) | 3 (20%) | 8 (22.2%) | ||||
| >10 | 12 (23.5%) | 1 (6.7%) | 11 (30.6%) | ||||
| AKI Stage | |||||||
| AKIN Criteria not Met | 48 | 32 (66.7%) | 2 (11.1%) | 30 (100%) | <0.001 | ||
| Stage 1 | 5 (10.4%) | 5 (27.8%) | 0 (0%) | ||||
| Stage 2 | 7 (14.6%) | 7 (38.9%) | 0 (0%) | ||||
| Stage 3 | 4 (8.3%) | 4 (22.2%) | 0 (0%) | ||||
| Elevated Creatinine (>1.3 mg/dL male, >1.1 mg/dL female) | 48 | 0 (0%) | 0 (0%) | 0 (0%) | n/a | ||
| Hematocrit Anemia (<38.8% male, <34.9% female) | 31 | 1 (3.2%) | 0 (0%) | 1 (5.9%) | 1.000 | ||
| Mean SD (Range) or Median (Range) | |||||||
| Age (years) | 54 | 29 (19, 59) | 26.9 (20, 40) | 29.5 (19, 59) | 0.229 | ||
| Number of Years Working Current Employer | 54 | 4.7 (0.03, 35.9) | 3.6 (0.03, 18.0) | 6.6 (0.8, 35.9) | 0.226 | ||
| Baseline Serum Creatinine (mg/dL) | 48 | 1.0 (0.7, 1.3) | 1.0 (0.7, 1.3) | 1.0 (0.8, 1.2) | 1.000 | ||
| Change (mg/dL) | 48 | 0.1 (-0.2, 3.3) | 1.2 (0.2, 3.3) | 0 (-0.2, 0.5) | <0.001 | ||
| Percent Change (%) | 48 | 10.0 (-22.2, 330.0) | 139.2 (16.7, 330.0) | 0 (-22.2, 62.5) | <0.001 | ||
| Ratio (Enrollment:Baseline) | 48 | 1.1 (0.8, 4.3) | 2.4 (1.2, 4.3) | 1.0 (0.8, 1.6) | <0.001 | ||
| Baseline Hematocrit (%) | 31 | 45 (38, 49) | 45.5 (39, 49) | 44 (38, 48) | 0.594 | ||
| Change (%) | 30 | -0.6 (-12, 8) | -9.0 (-12, -3.6) | 1.0 (-1, 8) | <0.001 | ||
| Percent Change (%) | 30 | -1.4 (-25.5, 19.5) | -20.5 (-25.5, -9.2) | 2.1 (-2.3, 19.5) | <0.001 | ||
| Ratio (Enrollment:Baseline) | 30 | 0.99 (0.75, 1.2) | 0.79 (0.75, 0.91) | 1.02 (0.98, 1.2) | <0.001 | ||
| Days Elapsed from Baseline | 48 | 180 (29, 361) | 92.5 (29, 188) | 255.5 (57, 361) | <0.001 | ||
| Baseline eGFR | 48 | 101.3 (69.0, 127.8) | 102.5 (69.0, 127.8) | 101.3 (75.7, 123.4) | 0.900 | ||
| Baseline Creatinine Clearance (mL/min) | 48 | 106.5 (70.8, 189.0) | 110.6 (70.8, 189.0) | 103.7 (88.6, 172.5) | 0.280 | ||
| Decrease from Baseline (mL/min) | 48 | 9.6 (-32.5, 113.4) | 57.9 (10.1, 113.4) | 0 (-32.5, 38.2) | <0.001 | ||
*Number of participants on whom data was available.
^Most recent laboratory data recorded within the prior year.
Fig 1Relationship between toenail trace element concentrations (log10-mg/kg dry nail mass) and serum creatinine level (mg/dL).
Toenail trace element concentrations (mg/kg dry nail mass), by quartile, for renal case patients and controls.
| Control | Case | ALL | No AKI | AKI | ALL | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 36 (66.7%) | 18 (33.3%) | 54 (100%) | p-value | N | 32 (66.7%) | 16 (33.3%) | 48 (100%) | p-value | ||
| Range | 39 | 0.05–51.24 | 0.18–42.65 | 0.06–51.24 | 35 | 0.06–51.24 | 0.18–42.65 | 0.06–51.24 | |||
| 25th Percentile | 0.10 | 0.82 | 0.15 | 0.002 | 0.09 | 1.06 | 0.13 | 0.001 | |||
| 50th Percentile | 0.21 | 1.55 | 0.70 | <0.001 | 0.23 | 2.56 | 0.82 | 0.015 | |||
| 75th Percentile | 0.70 | 5.78 | 2.04 | 0.471 | 0.70 | 7.72 | 3.45 | 0.586 | |||
| Range | 54 | 2.71–374.73 | 7.25–344.34 | 2.71–374.73 | 48 | 8.62–374.74 | 7.25–344.34 | 7.254–374.73 | |||
| 25th Percentile | 25.54 | 59.64 | 28.67 | 0.005 | 27.90 | 48.43 | 29.81 | 0.019 | |||
| 50th Percentile | 50.92 | 98.94 | 61.81 | 0.020 | 56.33 | 102.97 | 61.81 | 0.064 | |||
| 75th Percentile | 82.23 | 150.57 | 100.67 | 0.082 | 78.99 | 165.26 | 106.39 | 0.051 | |||
| Range | 22 | 0.06–0.56 | 0.20–0.95 | 0.06–0.95 | 17 | 0.06–0.56 | 0.68–0.95 | 0.06–0.95 | |||
| 25th Percentile | 0.17 | 0.44 | 0.17 | 0.002 | 0.17 | 0.68 | 0.20 | 0.002 | |||
| 50th Percentile | 0.32 | 0.79 | 0.33 | 0.050 | 0.31 | 0.90 | 0.34 | 0.002 | |||
| 75th Percentile | 0.46 | 0.93 | 0.50 | <0.001 | 0.43 | 0.95 | 0.52 | <0.001 | |||
| Range | 49 | 0.10–13.60 | 0.97–17.19 | 0.10–17.19 | 46 | 0.10–13.60 | 0.97–17.19 | 0.10–17.19 | |||
| 25th Percentile | 1.02 | 2.07 | 1.51 | 0.062 | 0.95 | 2.07 | 1.36 | 0.072 | |||
| 50th Percentile | 2.31 | 2.76 | 2.32 | 0.735 | 2.31 | 3.35 | 2.32 | 0.310 | |||
| 75th Percentile | 4.43 | 6.10 | 5.03 | 0.344 | 3.56 | 7.36 | 4.33 | 0.214 | |||
| Range | 51 | 3.18–368.25 | 3.31–355.71 | 3.18–368.25 | 45 | 3.18–266.91 | 3.31–355.71 | 3.18–355.71 | |||
| 25th Percentile | 22.69 | 33.51 | 23.63 | 0.390 | 22.69 | 31.60 | 23.63 | 0.607 | |||
| 50th Percentile | 49.98 | 81.89 | 61.22 | 0.226 | 49.98 | 86.16 | 61.22 | 0.202 | |||
| 75th Percentile | 110.05 | 120.73 | 110.81 | 0.865 | 98.33 | 127.50 | 110.05 | 0.692 | |||
| Range | 10 | 0.01–0.06 | 0.02–0.80 | 0.01–0.80 | 10 | 0.01–0.06 | 0.015–0.80 | 0.01–0.80 | |||
| 25th Percentile | 0.01 | 0.07 | 0.03 | 0.313 | 0.01 | 0.07 | 0.03 | 0.313 | |||
| 50th Percentile | 0.03 | 0.15 | 0.10 | 0.590 | 0.03 | 0.15 | 0.10 | 0.590 | |||
| 75th Percentile | 0.06 | 0.33 | 0.18 | 0.288 | 0.06 | 0.33 | 0.18 | 0.269 | |||
| Range | 54 | 0.31–46.91 | 2.41–14.06 | 0.31–46.91 | 48 | 0.31–46.91 | 2.41–14.06 | 0.31–46.91 | |||
| 25th Percentile | 2.85 | 3.67 | 3.06 | 0.083 | 3.11 | 3.56 | 3.28 | 0.261 | |||
| 50th Percentile | 3.79 | 4.31 | 3.91 | 0.341 | 4.15 | 4.01 | 4.11 | 0.914 | |||
| 75th Percentile | 4.97 | 6.47 | 5.21 | 0.425 | 5.09 | 6.51 | 5.23 | 0.307 | |||
| Range | 54 | 7.17–1773.46 | 62.08–425.09 | 7.17–1773.46 | 48 | 7.17–1773.46 | 62.08–425.09 | 7.167–1773.46 | |||
| 25th Percentile | 74.28 | 78.26 | 76.39 | 0.852 | 74.28 | 75.18 | 74.28 | 0.854 | |||
| 50th Percentile | 98.79 | 96.36 | 98.79 | 0.869 | 104.25 | 85.99 | 98.79 | 0.410 | |||
| 75th Percentile | 200.06 | 129.06 | 156.69 | 0.527 | 167.89 | 118.23 | 151.98 | 0.414 | |||
| Range | 21 | 0.03–0.56 | 0.02–0.35 | 0.02–0.56 | 19 | 0.03–0.56 | 0.02–0.35 | 0.02–0.56 | |||
| 25th Percentile | 0.08 | 0.06 | 0.08 | 0.847 | 0.08 | 0.06 | 0.06 | 0.801 | |||
| 50th Percentile | 0.27 | 0.13 | 0.16 | 0.317 | 0.14 | 0.16 | 0.16 | 0.997 | |||
| 75th Percentile | 0.38 | 0.22 | 0.33 | 0.167 | 0.32 | 0.22 | 0.32 | 0.411 | |||
| Range | 23 | 0.32–1.66 | 0.65–0.95 | 0.32–1.66 | 19 | 0.32–1.66 | 0.65–0.95 | 0.32–1.66 | |||
| 25th Percentile | 0.55 | 0.74 | 0.64 | 0.112 | 0.60 | 0.65 | 0.64 | 0.925 | |||
| 50th Percentile | 0.70 | 0.85 | 0.73 | 0.631 | 0.72 | 0.86 | 0.73 | 0.402 | |||
| 75th Percentile | 0.87 | 0.90 | 0.87 | 0.993 | 0.83 | 0.95 | 0.86 | 0.597 | |||
| Range | 21 | 0.01–0.05 | 0.01–0.21 | 0.006–0.21 | 19 | 0.006–0.04 | 0.006–0.21 | 0.006–0.21 | |||
| 25th Percentile | 0.01 | 0.02 | 0.015 | 0.576 | 0.01 | 0.02 | 0.01 | 0.968 | |||
| 50th Percentile | 0.02 | 0.03 | 0.02 | 0.513 | 0.02 | 0.02 | 0.02 | 0.828 | |||
| 75th Percentile | 0.03 | 0.09 | 0.04 | 0.201 | 0.02 | 0.11 | 0.03 | 0.122 | |||
| Range | 31 | 0.03–0.25 | 0.06–0.48 | 0.03–0.48 | 28 | 0.03–0.25 | 0.06–0.48 | 0.03–0.48 | |||
| 25th Percentile | 0.08 | 0.12 | 0.08 | 0.284 | 0.08 | 0.12 | 0.08 | 0.292 | |||
| 50th Percentile | 0.12 | 0.14 | 0.12 | 0.464 | 0.12 | 0.14 | 0.26 | 0.622 | |||
| 75th Percentile | 0.16 | 0.15 | 0.15 | 0.794 | 0.19 | 0.15 | 0.17 | 0.604 | |||
| Range | 21 | 0.02–1.88 | 0.06–0.18 | 0.02–1.88 | 16 | 0.02–0.25 | 0.07–0.18 | 0.02–0.25 | |||
| 25th Percentile | 0.06 | 0.06 | 0.06 | 0.506 | 0.06 | 0.07 | 0.06 | 0.648 | |||
| 50th Percentile | 0.07 | 0.09 | 0.07 | 0.666 | 0.07 | 0.10 | 0.07 | 0.587 | |||
| 75th Percentile | 0.19 | 0.14 | 0.18 | 0.902 | 0.09 | 0.18 | 0.11 | 0.145 | |||
| Range | 8 | 0.004–0.01 | 0.006–0.03 | 0.004–0.03 | 7 | 0.004–0.01 | 0.006–0.03 | 0.004–0.03 | |||
| 25th Percentile | 0.006 | 0.006 | 0.006 | 0.912 | 0.005 | 0.006 | 0.006 | 0.953 | |||
| 50th Percentile | 0.009 | 0.01 | 0.01 | 0.479 | 0.008 | 0.01 | 0.01 | 0.517 | |||
| 75th Percentile | 0.01 | 0.03 | 0.01 | 0.062 | 0.01 | 0.03 | 0.01 | 0.101 | |||
| Range | 13 | 0.07–1.21 | 0.34–6.96 | 0.07–6.96 | 11 | 0.07–1.21 | 0.72–6.96 | 0.07–6.96 | |||
| 25th Percentile | 0.22 | 0.42 | 0.35 | 0.954 | 0.32 | 0.72 | 0.35 | 0.532 | |||
| 50th Percentile | 0.57 | 0.72 | 0.72 | 0.971 | 0.41 | 1.88 | 0.72 | 0.172 | |||
| 75th Percentile | 1.04 | 1.88 | 1.19 | 0.704 | 0.97 | 6.96 | 1.21 | 0.053 |
*Statistically significant at p<0.05.
Toenail trace element concentrations (mg/kg dry nail mass), proportions by quartile, for renal case patients and controls.
| Control | Case | ALL | RR (95% CI) | No AKI | AKI | ALL | RR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 36 (66.7%) | 18 (33.3%) | 54 (100%) | p-value | N | 32 (66.7%) | 16 (33.3%) | 48 (100%) | p-value | ||||
| >25th Percentile | 39 | 12 (57.1%) | 18 (100%) | 30 (76.9%) | 0.002 | 11.9 (5.1, 28.2) | 35 | 10 (52.6%) | 16 (100%) | 26 (74.3%) | 0.001 | 12.2 (5.2, 28.9) | |
| >50th Percentile | 39 | 5 (23.8%) | 14 (77.8%) | 19 (48.7%) | 0.001 | 3.7 (1.5, 9.3) | 35 | 4 (21.1%) | 14 (87.5%) | 18 (51.4%) | <0.001 | 6.6 (1.5, 29.1) | |
| >75th Percentile | 39 | 1 (4.8%) | 8 (44.4%) | 9 (23.1%) | 0.006 | 2.7 (1.5, 4.7) | 35 | 1 (5.3%) | 8 (50%) | 9 (25.7%) | 0.005 | 2.9 (1.5, 5.4) | |
| >25th Percentile | 54 | 24 (66.7%) | 16 (88.9%) | 40 (74.1%) | 0.106 | 2.8 (0.7, 10.8) | 48 | 23 (71.9%) | 14 (87.5%) | 37 (77.1%) | 0.293 | 2.1 (0.6, 7.9) | |
| >50th Percentile | 54 | 14 (38.9%) | 13 (72.2%) | 27 (50%) | 0.042 | 2.6 (1.1, 6.3) | 48 | 12 (37.5%) | 12 (75%) | 24 (50%) | 0.030 | 3.0 (1.1, 8.1) | |
| >75th Percentile | 54 | 5 (13.9%) | 9 (50%) | 14 (25.9%) | 0.008 | 2.9 (1.4, 5.8) | 48 | 5 (15.6%) | 9 (56.3%) | 14 (29.2%) | 0.006 | 3.1 (1.4, 6.8) | |
| >25th Percentile | 22 | 13 (72.2%) | 4 (100%) | 17 (77.3%) | 0.535 | 3.0 (1.3, 7.1) | 17 | 11 (78.6%) | 3 (100%) | 14 (82.4%) | 1.000 | 1.9 (0.8, 4.5) | |
| >50th Percentile | 22 | 8 (44.4%) | 3 (75%) | 11 (50%) | 0.586 | 3.0 (0.4, 25.8) | 17 | 6 (42.9%) | 3 (100%) | 9 (52.9%) | 0.206 | 6.3 (0.4, 15.4) | |
| >75th Percentile | 22 | 3 (16.7%) | 3 (75%) | 6 (27.3%) | 0.046 | 3.0 (1.3, 7.2) | 17 | 2 (14.3%) | 3 (100%) | 5 (29.4%) | 0.015 | 15.2 (6.3, 36.8) |
*Statistically significant at p<0.05.
±Because complete separation was observed, a correction (+ 0.5 to each cell frequency) was utilized to obtain RR estimate.
Fig 2Relationship between toenail nickel concentrations (log10-mg/kg dry nail mass) and select physiologic parameters.
Characteristics of subjects who developed CKD of unknown etiology.
| Case 1 | Case 2 | |
|---|---|---|
| Sex | Male | Male |
| Age (years) | 30.6 | 33.1 |
| Month of Acute Presentation | June 2016 | April 2017 |
| Occupation | Seasonal sugarcane seed cutter; not working in the 1 month prior | Seasonal sugarcane seed cutter; working in the 1 month prior |
| Healthy Baseline | ||
| Creatinine (mg/dL) | 1.2 | 1.3 |
| Hematocrit (%) | Unknown | 42 |
| Hemoglobin (g/dL) | Unknown | Unknown |
| Leukocytes (cells/mm3) | Unknown | Unknown |
| Acute Presentation | ||
| Creatinine (mg/dL) | 1.4 | 2.97 |
| Hematocrit (%) | 32.0 | 31.3 |
| Hemoglobin (g/dL) | Unknown | 10.4 |
| Leukocytes (cells/mm3) | Unknown | 10400 |
| AKI Stage | AKIN criteria not met | 2 |
| Number of Days from Baseline to | ||
| Acute Visit | 30 | 97 |
| Number of Days from Acute to | ||
| CKD Diagnosis | 508 | 93 |
| CKD Stage | 3 | 3 |
| Concentration of Trace Element in Toenail (mg/kg) | ||
| Nickel | 0.24 | 0.48 |
| Aluminum | 62.64 | 30.47 |
| Vanadium | 0.20 | <MDL |
| Manganese | 1.63 | 1.36 |
| Iron | 81.89 | 15.46 |
| Cobalt | <MDL | 0.02 |
| Copper | 4.98 | 3.06 |
| Zinc | 134.62 | 72.11 |
| Arsenic | 0.11 | <MDL |
| Selenium | 0.84 | <MDL |
| Cadmium | <MDL | <MDL |
| Mercury | 0.12 | 0.13 |
| Lead | 0.06 | <MDL |
| Uranium | <MDL | <MDL |
| Chromium | 0.42 | <MDL |
*Reliance on retrospective review of medical records for clinical parameters resulted in unknown values for measurements not studied during clinical encounter.